Results 91 to 100 of about 25,762 (279)
BMC Nephrology, 2019 Background Atypical hemolytic uremic syndrome (aHUS) is a disorder of the microvasculature with hemolytic anemia, thrombocytopenia and acute kidney injury.
Subagini Nagarajah +7 more
doaj +1 more source
Romanian Journal of Internal Medicine, 2022 Introduction. The aim was to evaluate the effect of therapeutic plasma exchange (TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome (aHUS), and additionally, to examine the reliability of discontinuation of ...
Yeter Hasan H. +5 more
doaj +1 more source
When the environment and mutations affect organ systems [PDF]
, 2017 Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) with a genetic predisposition. Like other TMAs, it presents clinically with thrombocytopenia and microangiopathic hemolytic anemia, which is accompanied by disruption of
Abu Ghanimeh, Mouhanna +3 more
core +1 more source
Probiotic Development Strategy Centered on Stability and Regulatory Considerations
Comprehensive Reviews in Food Science and Food Safety, Volume 25, Issue 1, January 2026.ABSTRACT The development of probiotic strains has become a major focus in both academic and industrial research, driven by their health benefits and growing consumer demand. However, functional outcomes demonstrated under laboratory conditions often fail to align with the stability and large‐scale performance required for industrial applications ...
Hye Kim +5 more
wiley +1 more source
Atypical haemolytic-uraemic syndrome caused by factor H mutation: case report and new management strategies in children [PDF]
, 2012 Atypical haemolytic uraemic syndrome is causedby alternative complement pathway dysregulation. It has recently been recognised that most cases are due to genetic factors and a growing list of mutations has been described.
Araújo, L. +5 more
core
Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizimab treatment [PDF]
, 2016 Background: Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS). Guidelines discuss the importance of prompt treatment. We report a post hoc analysis investigating the effect of baseline factors, including patient characteristics and ...
Ardissimo, Gianluigi +5 more
core +2 more sources
Delayed‐Onset Hemolysis in a Case of Hemolytic Uremic Syndrome: A Diagnostic Challenge
Case Reports in Hematology, Volume 2026, Issue 1, 2026.Background Hemolytic uremic syndrome is a rare thrombotic microangiopathy characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury. While commonly reported in children, adult‐onset presentations are less frequent and often atypical, leading to diagnostic delays.
Muhammad Younas +4 more
wiley +1 more source
Complement regulator CD46: Genetic variants and disease associations [PDF]
, 2015 Membrane cofactor protein (MCP; CD46) is an ubiquitously expressed complement regulatory protein that protects host cells from injury by complement.
Atkinson, John P, Liszewski, M. Kathryn
core +2 more sources
Atypical Hemolytic Uremic Syndrome: A Case Report [PDF]
Cureus, 2019 Hemoytic uremic syndrome (HUS) is a rare type of thrombotic microangiopathies. Manifestations include thrombocytopenia, microangiopathic hemolytic anemia, and thrombi in small blood vessels. The prognosis is poor. Herein, we present a case of atypical HUS, which is very rare.
Mohammed, Sohaib K +4 more
openaire +2 more sources
Journal of Clinical Pharmacy and Therapeutics, Volume 2026, Issue 1, 2026.Background Ravulizumab represents the inaugural long‐acting complement C5 inhibitor that has received approval in various countries around the globe for individuals diagnosed with generalized myasthenia gravis (gMG) who are positive for anti‐acetylcholine receptor antibodies.
Yakun Wang +5 more
wiley +1 more source